Presentation is loading. Please wait.

Presentation is loading. Please wait.

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,

Published byGisle Nordli Modified over 5 years ago

Similar presentations

Presentation on theme: "A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,"— Presentation transcript:

1 A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy, MD, Thomas Harper, MD, Attilio Boner, MD, István Laki, MD, Michael Engel, MD, Georges El Azzi, MD, Petra Moroni-Zentgraf, MD, Helen Finnigan, MSc, Eckard Hamelmann, MD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 5, Pages (November 2017) DOI: /j.jaci Copyright © 2017 The Authors Terms and Conditions

2 Journal of Allergy and Clinical Immunology 2017 140, 1277-1287DOI: (10
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 The Authors Terms and Conditions

3 Fig 1 Study design (A) and CONSORT diagram (B). Usual background therapy is defined as high-dose ICSs (>400 μg budesonide or equivalent) plus 1 or more controller therapies (eg, a LABA or LTRA) or medium-dose ICSs (  μg budesonide or equivalent) plus 2 or more controller therapies (eg, a LABA and/or LTRA and/or sustained-release theophylline). QD, Once daily. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 The Authors Terms and Conditions

4 Fig 2 Peak FEV1(0-3h) (A) and trough FEV1 (B) responses at week 12: full analysis set. Results are adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Error bars are ± SEs. Common baseline mean FEV1 is 1572 ± 346 mL. *P < .05; **P < .001 versus placebo Respimat. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 The Authors Terms and Conditions

5 Fig 3 FEF25-75 responses over 12 weeks: full analysis set. Results are adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Error bars are ± SEs. Common baseline mean FEF25-75 is 1393 ± 571 mL. *P < .05; **P < .001 versus placebo Respimat. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 The Authors Terms and Conditions

6 Fig 4 Peak FEV1(0-3h) percentage predicted (A) and trough FEV1 percentage predicted (B) responses at week 12: full analysis set. Results adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Error bars are ± SEs. Common baseline mean FEV1 percentage predicted is 81.6 ± 11.5. *P < .05; **P < .001 versus placebo Respimat. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 The Authors Terms and Conditions

7 Fig 5 Trough FEV1/FVC responses over 12 weeks: full analysis set. Results are adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Error bars are ± SEs. Common baseline mean FEV1/FVC is 77.4 ± 10.1. *P < .05 versus placebo Respimat. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 The Authors Terms and Conditions

Download ppt "A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Jonathan Malka, MD, David T

Jonathan Malka, MD, David T
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.
Asthma diagnosis and treatment: Filling in the information gaps

Asthma diagnosis and treatment: Filling in the information gaps
The prevalence of severe refractory asthma

The prevalence of severe refractory asthma
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled.

Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled.
Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial  Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial  Huib A.M. Kerstjens, MD, PhD, Bernd Disse,
Effect of montelukast for treatment of asthma in cigarette smokers

Effect of montelukast for treatment of asthma in cigarette smokers
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma  Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma  Christian Vogelberg, MD, PhD, Michael Engel, MD, István.
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Similar presentations

Ads by Google